Increased Activity of the Diastrophic Dysplasia Sulfate Transporter in Otosclerosis and Its Inhibition by Sodium Fluoride

Otology and Neurotology

Volumn 24, Issue 6, 2003, Pages 854-862

  Bozorg Grayeli, Alexis ^a,b   Escoubet, Brigitte ^a   Bichara, Maurice ^a   Julien, Nicolas ^b   Silve, Caroline ^a   Friedlander, Gérard ^a   Sterkers, Olivier ^a,b   Ferrary, Evelyne ^a  

^a INSERM   (France)

^b BEAUJON HOSPITAL   (France)

Author keywords

Diastrophic dysplasia sulfate transporter; Hearing loss; Otosclerosis; Pathophysiology; Sodium fluoride

Indexed keywords

ALKALINE PHOSPHATASE; FLUORIDE SODIUM; FORSKOLIN; VERAPAMIL;

ADULT; ARTICLE; BONE METABOLISM; BONE TURNOVER; CELL CULTURE; CLINICAL ARTICLE; DYSPLASIA; ENZYME ACTIVITY; EXTERNAL AUDITORY CANAL; FEMALE; HUMAN; HUMAN CELL; MALE; OSTEODYSTROPHY; OTOSCLEROSIS; PATHOPHYSIOLOGY; PERCEPTION DEAFNESS; PRIORITY JOURNAL; RIBONUCLEASE PROTECTION ASSAY; STAPES;

ADULT; ALKALINE PHOSPHATASE; ANALYSIS OF VARIANCE; ANION TRANSPORT PROTEINS; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; CASE-CONTROL STUDIES; CELLS, CULTURED; EAR CANAL; FEMALE; FORSKOLIN; HEARING LOSS; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; OSTEOCHONDRODYSPLASIAS; OTOSCLEROSIS; PHENOTYPE; SODIUM FLUORIDE; STAPES; VERAPAMIL;

EID: 0242440365     PISSN: 15317129     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129492-200311000-00005     Document Type: Article

References (38)

1. Glasscock ME, Shambaugh GEJ. Diagnosis, indications for surgery, and medical therapy of otospongiosis (otosclerosis). In: Glasscock ME, Shambaugh GEJ, eds. Surgery of the Ear. Philadelphia: WB Saunders; 1990:370-87.
2. Donaldson JA, Snyder JM. Otosclerosis. In: Cummings CW, Frederickson JM, Harker LA, et al, eds. Otolaryngology-Head Neck Surgery, Vol. 4. St. Louis, MI: Mosby-Year Book; 1993:2997-3016.
3. Guild SR. Histologic otosclerosis. Ann Otol Rhinol Laryngol 1944;53:246-66.
4. Sabitha R, Ramalingam R, Ramalingam KK, et al. Genetics of otosclerosis. J Laryngol Otol 1997;111:109-12.
5. McKenna MJ, Kristiansen AG, Bartley ML, et al. Association of COL1A1 and otosclerosis. Am J Otol 1998;19:604-10.
6. Sziklai I, Grof J, Ribari O, et al. Possible role of peptides derived from otosclerotic bone in the mechanism of sensorineural hearing loss. Acta Otolaryngol (Stockh) 1985;100:253-9.
7. Hueb MM, Goycoolea MV, Paparella MM. Otosclerosis: the university of Minnesota temporal bone collection. Otolaryngol Head Neck Surg 1991;105:396-405.
8. Davis GL. Pathology of otosclerosis: a review. Am J Otolaryngol 1987;8:273-81.
9. Tomek MS, Brown MR, Mani SR, et al. Localization of a gene for otosclerosis to chromosome 15q25-q26. Hum Mol Gen 1998;7:285-90.
10. McKeehan WL, Wang F, Kan M. The heparan sulfate-fibroblast growth family: diversity of structure and functio. Prog Nucleic Acid Res Mol Biol 1998;59:135-76.
11. Taipale J, Keski-Oja J. Growth factors in the extracellular matrix. FASEB J 1997;11:51-9.
12. Bodo M, Carinci P, Venti G, et al. Glycosaminoglycan metabolism and cytokine release in normal and otosclerotic human bone cells interleukin-1 treated. Connect Tiss Res 1997;36:231-40.
13. Bodo M, Venti G, Baroni T, et al. Phenotypes of in vitro human otosclerotic cells and its modulation by TGFβ. Cell Mol Biol 1995;41:1039-49.
14. Locci P, Becchetti E, Venti G, et al. Glycosaminoglycan metabolism in otosclerotic bone cells. Biol Cell 1996;86:73-8.
15. Ribari O, Pereplica M, Sziklai I. Oversulfated muccopolysaccharides in the otosclerotic bone. Acta Otolaryngol (Stockh) 1991;111:362-5.
16. Satoh H, Susaki M, Shukunami C, et al. Functional analysis of diastrophic dysplasia sulfate transporter, its involvement in growth regulation of chondrocytes mediated by sulfated proteoglycans. J Biol Cell 1998;273:12307-15.
17. Rossi A, Bonaventure J, Delezoide A-L, et al. Undersulfatation of proteoglycans synthesized by chondrocytes from a patient with achondrogenesis type 1B homozygous for an L483P substitution in the diastrophic dysplasia sulfate transporter. J Biol Chem 1996;271:18456-64.
18. Bretlau P, Salomon G, Johnsen NJ. Otospongiosis and sodium fluoride, a clinical double-blind, placebo controlled study on sodium fluoride treatment in otospongiosis. Am J Otol 1989;10:20-2.
19. Chevance LG. Une explication biochimique et cytologique de l'otospongiose cochléaire. Acta Otolaryngol (Stockh) 1976;81:200-3.
20. House HP, Linthicum FHJ. Sodium fluoride and the otosclerotic lesion. Arch Otolaryngol 1974;100:427-30.
21. Caverzasio J, Palmer G, Bonjour JP. Fluoride: mode of action. Bone 1998;22:585-9.
22. Bozorg Grayeli A, Sterkers O, Roulleau P, et al. Parathyroid hormone receptor expression and function in otosclerosis. Am J Physiol 1999;277:E1005-E1012.
23. Kempson SA, Kim JK, Northrup TE, et al. Alkaline phosphatase in adaptation to low dietary phosphate intake. Am J Physiol 1979;6: E465-E473.
24. Bradford MM. A rapid and sensitive method for quantification of microgram quantities of protein using the principle of protein-dose binding. Anal Biochem 1976;72:248-52.
25. Escoubet B, Coureau C, Blot-Chabaut M, et al. Corticosteroid receptor mRNA expression is unaffected by corticosteroids in rat kidney, heart and colon. Am J Physiol 1996;270:C1343-C1353.
26. Hästbacka J, de la Chapelle A, Mahtani MM, et al. The diastrophic dysplasia gene encodes a novel sulfate transporter: positional cloning by fine-structure linkage disequilibrium mapping. Cell 1994;78:1073-87.
27. Elgavish A, Smith J, Pillion DJ, et al. Sulfate transport in human lung fibroblasts (IMR-90). J Cell Physiol 1985;125:243-50.
28. Maurizi M, Binaglia L, Donti E, et al. Morphological and functional characteristics of human temporal bone cell cultures. Cell Tissue Res 1983;229:505-13.
29. Rosenberg GD, Tubergen LB. Sex-related differences in composition of otosclerotic and unafflicted stapes. Am J Otol 1996;17:709-12.
30. Paiva LJ, De Jorge FB. Sulfur metabolism in otosclerosis. Arch Otolaryngol 1969;90:56-7.
31. Rossi A, Kaitila I, Wilcox WR, et al. Proteoglycan sulfatation in cartilage and cell cultures from patients with sulfate dysplasia sulfate transporter chondrodysplasias: relationship to clinical severity and indications on the role of intracellular sulfate production. Mat Biol 1998;17:361-9.
32. Thalmann I, Thallinger G, Thalmann R. Otosclerosis: a local manifestation of a generalized connective tissue disorder? Am J Otolaryngol 1987;8:308-16.
33. Mc Phee JR, Gordon MA, Ruben RJ, et al. Evidence of abnormal stromylesin mRNA expression in suspected carriers of otosclerosis. Arch Otolaryngol Head Neck Surg 1993;119:1108-16.
34. Gordon MA, Mc Phee JR, Van De Water TR, et al. Aberration of the tissue collagenase system in association with otosclerosis. Am J Otol 1992;13:398-407.
35. Schrader M, Poppendieck J, Weber B. Immunohistologic findings in otosclerosis. Ann Otol Rhinol Laryngol 1990;99:349-52.
36. Yoo TJ, Shea JJ, Floyd RA. Enchondral cartilage rests collagen-induced auto-immunity: a possible pathogenetic mechanism of otosclerosis. Am J Otolaryngol 1987;8:317-324.
37. Bretlau P, Causse J, Causse J-B, et al. Otospongiosis and sodium fluoride, a blind experimental and clinical evaluation of the effect of sodium fluoride treatment in patients with otospongiosis. Ann Otol Rhinol Laryngol 1985;94:103-7.
38. Pak CY, Sakhaee K, Rubin CD, et al. Sustained-release sodium fluoride in the management of postmenopausal osteoporosis. Am J Med Sci 1997;313:23-32.